Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809141 | 0.86 | SIGMAR1 (0.46) | ALDH1A1KDM4ESIGMAR1TDP1LMNA | |
| SCHEMBL23809110 | 0.83 | LMNA (0.37) | ALDH1A1MAPTSIGMAR1LMNATMEM97 | |
| SCHEMBL26032241 | 0.82 | GAA (0.44) | ALDH1A1KDM4EMAPTGAASMN1; SMN2 | |
| SCHEMBL23809035 | 0.81 | ALOX15 (0.43) | ALDH1A1KDM4EGAASMN1; SMN2PTPN1 | |
| SCHEMBL23809108 | 0.81 | CXCR4 (0.39) | ALDH1A1KDM4EPTPN1SIGMAR1TDP1 | |
| SCHEMBL23809134 | 0.80 | HRH3 (0.44) | ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL26032247 | 0.79 | GAA (0.43) | ALDH1A1KDM4EGAASMN1; SMN2PTPN1 | |
| SCHEMBL23808978 | 0.79 | PIK3CD (0.43) | SIGMAR1HRH1 | |
| SCHEMBL16476786 | 0.77 | GAA (0.36) | ALDH1A1KDM4EMAPTGAASMN1; SMN2 | |
| SCHEMBL16479758 | 0.76 | GAA (0.41) | ALDH1A1KDM4EGAASMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885MAPT 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.